Skip to main content

Table 2 Serotype-specific average per-dose take rates for tOPV and bOPV determined in the clinical trials that compared both vaccines, and assumed in the DEB and global models

From: The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission

Setting

tOPV serotype

bOPV serotype

 

1

2

3

1

2

3

Clinical trials

Central and Southern India [25], 2 doses at 0 and 30 days of age

0.39

0.70

0.31

0.62

0.06

0.49

Bangladesh [26], 3-doses at 6, 10, and 14 weeks of age)

0.57

0.65

0.51

0.70

0.06

0.65

Calibrated DEB model within ranges from literature [17, 21]

Northwest Nigeria [4, 6, 9, 17, 19]

0.45

0.70

0.35

0.54

0

0.54

Northern India [5, 9, 17, 19]

0.35

0.60

0.27

0.42

0

0.42

Global model assumptions based on calibrated DEB model [20]

Lowest tier (e.g., Northern India)

0.35

0.60

0.27

0.42

0

0.42

Second tier (e.g., Northern Pakistan)

0.40

0.65

0.32

0.50

0

0.50

Third tier (e.g., Northwest Nigeria)

0.45

0.70

0.35

0.54

0

0.54

Fourth tier (e.g., Brazil)

0.50

0.72

0.40

0.60

0

0.60

Fifth tier (e.g., Philippines, Turkey)

0.55

0.73

0.45

0.70

0

0.70

Sixth tier (e.g., Russia, middle-income China)

0.60

0.74

0.50

0.75

0

0.75

Seventh tier (e.g., upper-income China, Israel)

0.65

0.75

0.55

0.80

0

0.80